Switch theme
Sign up to access all valuation multiples
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
2017
37
LTM Revenue $2.3M
Last FY EBITDA -$44.2M
$82.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioXcel Therapeutics has a last 12-month revenue (LTM) of $2.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, BioXcel Therapeutics achieved revenue of $2.3M and an EBITDA of -$44.2M.
BioXcel Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioXcel Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | XXX | $2.3M | XXX | XXX | XXX |
| Gross Profit | $2.3M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 5% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$44.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1949% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$64.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -2860% | XXX | XXX | XXX |
| Net Profit | -$53.4M | XXX | -$59.6M | XXX | XXX | XXX |
| Net Margin | -2320% | XXX | -2630% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $72.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BioXcel Therapeutics's stock price is $1.
BioXcel Therapeutics has current market cap of $7.1M, and EV of $82.0M.
See BioXcel Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82.0M | $7.1M | XXX | XXX | XXX | XXX | $-17.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BioXcel Therapeutics has market cap of $7.1M and EV of $82.0M.
BioXcel Therapeutics's trades at 36.2x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate BioXcel Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioXcel Therapeutics has a P/E ratio of -0.1x.
See valuation multiples for BioXcel Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.1M | XXX | $7.1M | XXX | XXX | XXX |
| EV (current) | $82.0M | XXX | $82.0M | XXX | XXX | XXX |
| EV/Revenue | 35.6x | XXX | 36.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 35.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioXcel Therapeutics's last 12 month revenue growth is 67%
BioXcel Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.8M for the same period.
BioXcel Therapeutics's rule of 40 is -11920% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioXcel Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioXcel Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 67% | XXX | 62% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1949% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -11920% | XXX | -1882% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1343% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2865% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioXcel Therapeutics acquired XXX companies to date.
Last acquisition by BioXcel Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . BioXcel Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioXcel Therapeutics founded? | BioXcel Therapeutics was founded in 2017. |
| Where is BioXcel Therapeutics headquartered? | BioXcel Therapeutics is headquartered in United States of America. |
| How many employees does BioXcel Therapeutics have? | As of today, BioXcel Therapeutics has 37 employees. |
| Who is the CEO of BioXcel Therapeutics? | BioXcel Therapeutics's CEO is Dr. Vimal Mehta, PhD. |
| Is BioXcel Therapeutics publicy listed? | Yes, BioXcel Therapeutics is a public company listed on NAS. |
| What is the stock symbol of BioXcel Therapeutics? | BioXcel Therapeutics trades under BTAI ticker. |
| When did BioXcel Therapeutics go public? | BioXcel Therapeutics went public in 2018. |
| Who are competitors of BioXcel Therapeutics? | Similar companies to BioXcel Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioXcel Therapeutics? | BioXcel Therapeutics's current market cap is $7.1M |
| What is the current revenue of BioXcel Therapeutics? | BioXcel Therapeutics's last 12 months revenue is $2.3M. |
| What is the current revenue growth of BioXcel Therapeutics? | BioXcel Therapeutics revenue growth (NTM/LTM) is 67%. |
| What is the current EV/Revenue multiple of BioXcel Therapeutics? | Current revenue multiple of BioXcel Therapeutics is 35.6x. |
| Is BioXcel Therapeutics profitable? | Yes, BioXcel Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
